Skip to content

San Bernardino Sun

67°F
Tuesday, February 24th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

9.335 +0.395 (+4.42%)
Streaming Delayed Price Updated: 1:14 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs. 
Via The Motley Fool
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Preview: Relay Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run ↗
This clinical-stage biotech focused on precision oncology therapies reported an insider sale amid a year of sharp share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Relay Therapeutics (RLAY) Stock Is Down 17% Today ↗
Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering. 
Via Benzinga
News headline image
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative... 
Via MarketMinute
Topics ETFs Government Initial Public Offering
News headline image
Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic. ↗
Sometimes insiders sell shares because their conviction is changing. Sometimes it's just about bookkeeping. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture
Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across... 
Via TokenRing AI
Topics Artificial Intelligence Economy Emissions
News headline image
Relay Therapeutics Inc (NASDAQ:RLAY) Reports Q3 2025 Earnings Miss and Clinical Progress ↗
Relay Therapeutics reports Q3 2025 results, missing revenue estimates. The biotech firm maintains a strong cash position to fund its clinical trials for lead drug RLY-2608 into 2029. 
Via Chartmill
Topics Earnings
News headline image
Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week ↗
The cancer-focused biotech has a bright future, according to one pundit. 
Via The Motley Fool
News headline image
Medtronic To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Relay (RLAY) Q2 Loss Narrows 41% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
Why Relay Therapeutics Plummeted by Nearly 14% Today ↗
Investors weren't happy with the company's latest effort at capital-raising. 
Via The Motley Fool
News headline image
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market ↗
Relay Therapeutics shares interim data for RLY-2608 from the ReDiscover study, showing a 57% clinical benefit rate. Oppenheimer downgrades Relay Therapeutics from Outperform to Perform, citing concerns... 
Via Benzinga
News headline image
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Dow Jumps Over 1% Following Last Week's Selloff: Investor Sentiment Improves, But Fear & Greed Index Remains In 'Fear' Zone ↗
 
Via Benzinga
Topics Stocks
News headline image
Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.